{"id":12059,"date":"2025-03-13T23:24:06","date_gmt":"2025-03-13T22:24:06","guid":{"rendered":"https:\/\/valintermed.com\/?p=12059"},"modified":"2025-03-13T23:24:06","modified_gmt":"2025-03-13T22:24:06","slug":"mieloproliferativnye-novoobrazovaniya-mpn","status":"publish","type":"post","link":"https:\/\/valintermed.com\/en\/medlibrary\/myeloproliferative-neoplasms-mpn\/","title":{"rendered":"Myeloproliferative neoplasms (MPN)"},"content":{"rendered":"
<\/div>\n

Myeloproliferative neoplasms (MPNs) are a group of hemato-oncological diseases characterized by abnormal proliferation of bone marrow cells. The main diseases in this group are polycythemia vera, essential thrombocythemia, and idiopathic myelofibrosis. These diseases are caused by mutations that lead to dysregulation of cell growth, which is manifested by an increase in the number of cells in the blood and their abnormal function. In MPNs, changes in blood composition are observed, including an increase in the number of red blood cells, white blood cells, and platelets, which entails the risk of thrombosis and, in some cases, progression to acute leukemia. Despite the presence of clinical manifestations and high morbidity, MPNs remain poorly understood in the context of pathogenesis and therapy.<\/p>\n

\n
\n

Content<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n